Sosei Group Corporation
4F Ichiban-cho FS Building
8 Ichiban-cho, Chiyoda-ku
51 articles with Sosei Group Corporation
Sosei Heptares and Biohaven Enter Global Collaboration and License Agreement to Advance Novel Small-Molecule CGRP Antagonist Portfolio
Sosei Group Corporation announces it has entered into a global collaboration and license agreement with Biohaven Pharmaceutical Holding Company Ltd..
Sosei Heptares' COVID-19 Program Identifies Potent Broad Spectrum Anti-Viral Small Molecules for Further Development
Program focused on inhibitors of SARS-CoV-2 main protease, a highly conserved protein essential for viral replication
Sosei Heptares and Aditum Bio create new company - Tempero Bio - to advance the clinical development of mGlu5 NAM program in neurological diseases
- Aditum Bio, established by industry veterans Joe Jimenez and Mark Fishman, to fund clinical development - Sosei Heptares to receive an upfront payment and strategic equity stake in Tempero Bio, plus future success-based milestone payments and tiered royalties
Sosei Heptares Successfully Raises US$200 million in International Offering of New Shares and Convertible Bonds
Sosei Group Corporation announces the successful completion of an International Offering of new shares and euro-yen denominated convertible bonds due 2025 that has raised a total of approximately $200 million.
The companies will work to discover, develop and commercialize novel therapies that modulate G protein-coupled receptor (GPCR) targets that AbbVie selects.
Sosei Heptares and Takeda Enter Into New Strategic Multi-target Research, Development and Commercialization Partnership
Collaboration combines Sosei Heptares' GPCR-focused StaR® and structure-based drug design capabilities with Takeda's discovery, development and therapeutic area expertise
Sosei Group Corporation inked a strategic multi-target partnership with Takeda Pharmaceutical to find, develop and commercialize small molecules and biologics that modulate G protein-coupled receptor targets. The initial focus will be on gastrointestinal targets.
Collaboration aims to discover and develop novel medicines that modulate G protein-coupled receptor (GPCR) targets across a range of diseases
In writing literally hundreds of stories this year, two BioSpace writers, Alex Keown and Mark Terry, found certain stories particularly intriguing or impactful. Some of those were such big topics that they were covered over a series of stories. Looking back at 2018, here are their Top 10.
MiNA Therapeutics remains on track with current development plans for small activating RNA medicines including clinical development of MTL-CEBPA drug candidate
Allergan and its development partner Sosei Group have voluntarily suspended clinical trials of HTL0018318 in Alzheimer’s and other types of dementia because of safety problems.
Sosei Group Corporation announces that Mr. Andrew Oakley, Executive Vice President and CFO, has resigned from the Company.
The 2018 American Association for Cancer Research (AACR) is being held in Chicago. Here’s a roundup of some of today’s company news.
Sosei Confirms New Data Demonstrating AZD4635, a Novel A2A Receptor Antagonist, Induces Anti-Tumor Immunity Alone and in Combination With Anti-PD-L1 in Preclinical Models
New data presented at 2018 AACR Meeting
Sosei Regains Worldwide Rights from Teva to Develop and Commercialize Novel Small Molecule CGRP Antagonists for Migraine and Other Severe Headaches
Sosei Group announced that it has regained worldwide rights from Teva Pharmaceutical Industries Limited to develop and commercialize lead candidate HTL0022562 and other novel small molecule CGRP antagonists for the treatment of migraine and other severe headaches.
The first patient has been dosed in an expansion cohort in the Phase 1b segment of the Phase 1 study in advanced solid tumours.
Sosei today announced that it will be restating selected financial statements previously issued by the Company.
Entry on the day will commence from 09:30 a.m.
Dr. Marshall will leave Sosei at the end of February 2018.
Sosei to Advance Clinical Development in Japan of HTL0018318 in Patients With Dementia With Lewy Bodies (DLB)
Initially, Sosei will undertake a Phase 2 proof-of-concept monotherapy study, expected to begin in Japan in 2018.